Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 4Not yet recruiting 3Recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × isatuximab × 30 days × Clear all
NCT04430894 2026-06-03

KRDI in Transplant-Eligible MM

Massachusetts General Hospital

Phase 2 Active not recruiting
50 enrolled 20 charts
Plasma cell

Multiple Myeloma

NCT06203912 2026-05-26

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
3 enrolled
Plasma cell

Multiple Myeloma

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
6 enrolled 5 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03104842 2026-05-15

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Universitätsklinikum Hamburg-Eppendorf

Phase 2 Active not recruiting
246 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡